Ruth McKernan of SV Health Investors noted that wearables and health data are driving medicine from generalized to personalized, and AI is already accelerating parts of drug discovery and optimizing patient selection for clinical trials. She also emphasized that some drug development processes cannot be rushed, and UK life science companies still need more funding to scale up.